EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease

Elizabeth R Volkmann iD, Holly Wilhalme, Donald P Tashkin, Grace Hyun J Kim iD, Jonathan Goldin, Alana Haussmann, Masataka Kuwana iD, Michael D Roth, Shervin Assassi iD

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25485 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Elizabeth R Volkmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Lung Diseases, Interstitial, Mycophenolic Acid, Cyclophosphamide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, U.S. Department of Defense, Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study investigated whether changes in circulating biomarkers predict progressive pulmonary fibrosis (PPF) in patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) receiving treatment.

Methods

Participants of the Scleroderma Lung Study II, which compared receiving mycophenolate mofetil (MMF) versus cyclophosphamide (CYC) for treating SSc‐ILD, who had blood samples at baseline and 12 months were included. Levels for C‐reactive protein (CRP), interleukin‐6, C‐X‐C motif chemokine ligand (CXCL) 4, CCL18, and Krebs von den Lungen (KL)‐6 were measured, and a logistic regression model evaluated relationships between changes in these biomarkers and the development of PPF by 24 months.

Results

A total of 92 of the 142 randomized participants had longitudinal biomarker measurements and the required clinical outcome data, with 19 participants (21%) meeting criteria for PPF. In the whole cohort, changes in KL‐6 levels were significantly correlated with PPF. KL‐6 increased in patients who developed PPF and decreased in patients who did not (mean change ± SD 365.68 ± 434.41 vs −207.45 ± 670.26; P < 0.001). In the arm of participants who received MMF alone, changes in CRP and CXCL4 levels were also significantly correlated with PPF. When added to an existing prediction model based on baseline factors associated with PPF in this cohort (sex, baseline reflux severity, and CXCL4 levels), the change in KL‐6 remained significantly associated with PPF (odds ratio 1.4; P = 0.0002).

Conclusion

Changes in the circulating levels of KL‐6 after treatment with MMF or CYC predicted PPF, even after adjusting for baseline factors associated with PPF. Measuring longitudinal KL‐6 in patients with SSc‐ILD may improve how we personalize therapy in patients with SSc‐ILD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicLung Diseases, InterstitialMycophenolic AcidCyclophosphamideMucin-1Immunosuppressive AgentsHumansMaleFemaleBiomarkersMiddle AgedTreatment OutcomeC-Reactive ProteinAgedAdultInterleukin-6Longitudinal StudiesChemokines, CC

Substanzen

BiomarkersMycophenolic AcidMUC1 protein, humanCyclophosphamideMucin-1Immunosuppressive AgentsC-Reactive ProteinCCL18 protein, humanInterleukin-6Chemokines, CC

Autor:innen und Institutionen

  • University of California, Los Angeles.
  • Nippon Medical School, Tokyo, Japan.
  • University of Texas Health Science Center at Houston.

ORCID-Profile: Elizabeth R Volkmann, Grace Hyun J Kim, Masataka Kuwana, Shervin Assassi

Förderung

  • NHLBI NIH HHS
  • U.S. Department of Defense
  • Hoffmann-La Roche
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Volkmann, E. R., Wilhalme, H., Tashkin, D. P., Kim, G. H. J., Goldin, J., Haussmann, A., Kuwana, M., Roth, M. D., & Assassi, S. (2025). Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care & Research. https://doi.org/10.1002/acr.25485

Vancouver

Volkmann ER, Wilhalme H, Tashkin DP, Kim GHJ, Goldin J, Haussmann A, et al. Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care & Research. 2025. doi:10.1002/acr.25485

BibTeX
@article{Volkmann2025,
  author = {Volkmann, Elizabeth R and Wilhalme, Holly and Tashkin, Donald P and Kim, Grace Hyun J and Goldin, Jonathan and Haussmann, Alana and Kuwana, Masataka and Roth, Michael D and Assassi, Shervin},
  title = {Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25485}
}
Kostenlos starten →